European Commission Approves ORKAMBI (lumacaftor/ivacaftor) for the Treatment of Children With Cystic Fibrosis Ages 1 to

05.07.2023 - Vertex Pharmaceuticals today announced that the European Commission has granted approval for the label extension of ORKAMBI (lumacaftor/ivacaftor) for the treatment of children with cystic fibrosis (CF) ages 1 to

Related Keywords

Australia ,Canada ,Sweden ,Ireland ,Barcelona ,Comunidad Autonoma De Cataluna ,Spain ,Austria ,Denmark ,Germany ,United Kingdom ,Republic Of Ireland ,Great Britain ,Silvia Gartner ,European Commission ,Coordinator Of The Pediatric Cystic Fibrosis Center ,European Union ,Pediatric Cystic Fibrosis Center ,